BioRestorative Therapies, a life sciences company focussed on adult stem cell-based therapies for various personal medical applications, has entered into a two-year collaborative research agreement with Pfizer to study human brown adipose tissue and cell lines.

Under the terms of the Agreement, BRT and Pfizer will jointly conduct a study titled “Development and Validation of a Human Brown Adipose Cell Model,” which will seek to further characterise the identity and metabolic function of these cell lines. BRT has accumulated a large collection of human brown adipose tissue samples, preadipocyte cell lines and immortalised cell lines for use in potentially developing a cell therapy product.

Mark Weinreb, chief executive officer of BRT, said, “Pfizer is a global pharmaceutical leader and we are very excited to be working with it on our ThermoStem programme. Research into human brown fat to date has suggested that brown fat is correlated with the maintenance and regulation of metabolism. Ultimately, we will look to determine if our cell lines have utility in the treatment of obesity, which is responsible for many diseases, including type 2 diabetes. We look forward to a productive research project for both our companies.”